

DAFTAR PUSTAKA

1. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2024;105(Suppl 4S):S117-S314.
2. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl.* 2022;12:7–11.
3. McCallion S. Biomarkers associated with AKI and CKD and their progression. London: Ulster University; 2023.
4. Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J, et al. Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. *Nephron.* 2024;148(2):113–123.
5. Indonesian Renal Registry. 13 th Annual report of Indonesian renal registry 2020. Jakarta: Perhimpunan Nefrologi Indonesia (PERNEFRI); 2023
6. Chen HH, Zhang YX, Lv J Le, Liu YY, Guo JY, Zhao L, et al. Role of sirtuins in metabolic disease-related renal injury. *Biomed Pharmacother.* 2023;161:1-11
7. Suwitra K. Penyakit ginjal kronik. In : Setiati S, editor. Ilmu Penyakit Dalam, Interna Publishing; 2014. p. 2159-2165.
8. Menn-Josephy H, Lee CS, Nolin A, Christov M, Rybin DV, Weinberg JM, et al. Renal interstitial fibrosis: an imperfect predictor of kidney disease progression in some patient cohorts. *Am J Nephrol.* 2016;44(4):289–299.
9. Jin Q, Ma F, Liu T, Yang L, Mao H, Wang Y, et al. Sirtuins in kidney diseases: potential mechanism and therapeutic targets. *Cell Commun Signal.* 2024;22(114) : 1-21
10. Wu H, Qiu Z, Wang L, Li W. Renal fibrosis: SIRT1 still of value. *Biomedicines.* 2024;12(9):1-20.
11. Wu QJ, Zhang TN, Chen HH, Yu XF, Le JL, Liu YY, et al. The sirtuin family in health and disease. *Signal Transduct Target Ther.* 2022;7:1-74.
12. Wang W, Sun W, Cheng Y, Xu Z, Cai L. Role of sirtuin-1 in diabetic nephropathy. *J Mol Med.* 2019;97:291–309.
13. Tovar-Palacio C, Noriega LG, Mercado A. Potential of polyphenols to restore SIRT1 and NAD⁺ metabolism in renal disease. *Nutrients.* 2022;14:1-33

14. Harun H, Veronike E, Kam A, Amelia R. Correlation between oxidative stress, SIRT1 Serum level, and eGFR on elderly. *Jurnal Penelitian Pendidikan IPA*. 2023;9(8):6432–8
15. Shao Y, Ren H, Lv C, Ma X, Wu C, Wang Q. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. *Endocrine*. 2017;55(1):130–138
16. Maeda S, Koya D, Araki SI, Babazono T, Umezono T, Toyoda M, et al. Association between singlenucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. *Clin Exp Nephrol*. 2011;15(3):381–390
17. Tang K, Sun M, Shen J, Zhou B. Transcriptional coactivator p300 and silent information regulator 1 (SIRT1) gene polymorphism associated with diabetic kidney disease in a Chinese cohort. *Exp Clin Endocrinol Diabetes*. 2017;125(8):530–537
18. Yan J, Wang J, He JC, Zhong Y. Sirtuin 1 in chronic kidney disease and therapeutic potential of targeting sirtuin 1. *Front Endocrinol*. 2022;13:1-6.
19. Moeller MJ, Kramann R, Lammers T, Hoppe B, Latz E, Ludwig PI, et al. New aspects of kidney fibrosis—from mechanisms of injury to modulation of disease. *Front Med*. 2022;8:1-16.
20. Liu T, Yang L, Mao H, Ma F, Wang Y, Li S, et al. Sirtuins as novel pharmacological targets in podocyte injury and related glomerular diseases. *Biomed Pharmacother*. 2022;155:1-13.
21. Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY. TGF- β in renal fibrosis: triumphs and challenges. *Future Med Chem*. 2020;12:853–66.
22. Tzavlaki K, Moustakas A. TGF-B signaling. *Biomolecules*. 2020;10:1-38.
23. Goebel EJ, Hart KN, McCoy JC, Thompson TB. Structural biology of the TGF β family. *Exp Biol Med*. 2019;244:1530–46.
24. Li J, Zou Y, Kantapan J, Su H, Wang L, Dechsupa N. TGF- β /Smad signaling in chronic kidney disease: Exploring post-translational regulatory perspectives. *Mol Med Rep*. 2024;30:1-13.
25. Kim KP, Williams CE, Lemmon CA. Cell matrix interactions in renal fibrosis. *Kidney and Dialysis*. 2022;2:607–24.

26. Wu W, Wang X, Yu X, Lan HY. Smad3 signatures in renal inflammation and fibrosis. *Int J Biol Sci.* 2022;18:2795–806.
27. Cao J, Hou R, Lu J, Zhang K, Zhao C, Jiang H, et al. The predictive value of β 2-MG and TGF- β for elderly hypertensive nephropathy. *Exp Ther Med.* 2019;17:2067-70.
28. Badurdeen Z, Alli-Shaik A, Ratnatunga NVI, Abeysekera TDJ, Wijetunge S, Hemage RKD, et al. Serum transforming growth factor-beta 1 and creatinine for early diagnosis of CKD of unknown or uncertain etiology phenotypes. *Kidney Int Rep.* 2023;8(2):368–72.
29. Mansour SG, Puthumana J, Coca SG, Gentry M, Parikh CR. Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review. *BMC Nephrol.* 2017;18(1):1-13.
30. Bharti N, Agrawal V, Kamthan S, Prasad N, Agarwal V. Blood TGF- β 1 and miRNA-21-5p levels predict renal fibrosis and outcome in IgA nephropathy. *Int Urol Nephrol.* 2023;55(6):1557–64.
31. Van Nguyen T, Ngo KD, Thi MH, Dam LTP, Huynh TQ. Evaluating the serum transforming growth factor-beta 1 level in chronic kidney disease caused by glomerulonephritis. *Nephrourol Mon.* 2021;13(2):1-5.
32. Rende U, Guller A, Goldys EM, Pollock C, Saad S. Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis. *J Physiol.* 2023;601:2801–26.
33. Champion CG, Sanchez-Ferras O, Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. *Can J Kidney Health Dis.* 2017;4:1-18.
34. S Mogre S, Brown AI, Koslover EF. Getting around the cell: Physical transport in the intracellular world. *Phys Biol.* 2020;17:1-47.
35. Kim JY, Jo J, Kim K, An HJ, Gwon MG, Gu H, et al. Pharmacological activation of SIRT1 ameliorates cisplatin-induced acute kidney injury by suppressing apoptosis, oxidative stress, and inflammation in mice. *Antioxidants.* 2019;8(8):1-12.
36. Amelia R, Said FM, Yasmin F, Harun H, Tofrizal T. The anti-inflammatory activity of probiotic Dadiah to activate Sirtuin-1 in inhibiting diabetic nephropathy progression. *J Diabetes Metab Disord.* 2023;22(2):1425–42.

37. Bazyluk A, Malyszko J, Hryszko T, Zbroch E. State of the art – sirtuin 1 in kidney pathology – clinical relevance. *Adv Med Sci.* 2019;64:356–64.
38. Harun H, Yanwirasti Y, Purwanto B, Rahayuningsih EP. The effect of giving dadih on malondialdehyde levels and renal interstitial fibrosis at aging kidney. *Open Access Maced J Med Sci.* 2020;8:293–6.
39. Harun H, Yanwirasti Y, Purwanto B, Rahayuningsih EP. The effect of giving dadih on manganese superoxide dismutase gene expression and malondialdehyde levels at aging kidney. *Open Access Maced J Med Sci.* 2020;8:525–8.
40. Hidayangsih PS, Tjandrarini DH, Widya Sukoco NE, Sitorus N, Dharmayanti I, Ahmadi F. Chronic kidney disease in Indonesia: evidence from a national health survey. *Osong Public Health Res Perspect.* 2023;14(1):23–30.
41. Peixoto AJ, Bakris GL. Approach to the patient with hypertensive nephrosclerosis. *Chronic Ren Dis.* 2019;2:737–52.
42. Chanvillard L, Tammaro A, Sorrentino V. NAD⁺ metabolism and interventions in premature renal aging and chronic kidney disease. *Cells.* 2023;12:1-32.
43. Teixeira CSS, Cerqueira NMFS, Gomes P, Sousa SF. A molecular perspective on sirtuin activity. *Int J Mol Sci.* 2020;21:1–20.
44. Sousa C, Mendes AF. Monoterpenes as sirtuin-1 activators: therapeutic potential in aging and related diseases. *Biomolecules.* 2022;12:1-20.
45. Zbroch E, Bazyluk A, Malyszko J, Koc-Zorawska E, Rydzewska A, Rosolowska, et al. The serum concentration of anti-aging proteins, sirtuin1 and α Klotho in patients with end-stage kidney disease on maintenance hemodialysis. *Clin Interv Aging.* 2020;15:387–93.
46. Hong YA, Kim JE, Jo M, Ko GJ. The role of sirtuins in kidney diseases. *Int J Mol Sci.* 2020;21(18):1–21.
47. Wang M, Lin H. Understanding the function of mammalian sirtuins and protein lysine acylation. *Annu Rev Biochem.* 2021;44:245-85.
48. Shahgaldi S, Kahmini FR. A comprehensive review of Sirtuins: with a major focus on redox homeostasis and metabolism. *Life Sci.* 2021;282:1-13.

49. Rahimi M, Ghanbari S, Khazaei M, Niroman E. Comparison of sirtuin 1 level and related blood factors in diabetic and healthy subjects. *Pediatr Endocrinol Diabetes Metab.* 2020;26(1):17–21.
50. Gonçalves GHF, Kuwabara KL, Faria NF de O, Goes MF da S, Roggerio A, Avakian SD, et al. Sirtuin 1 and vascular function in healthy women and men: a randomized clinical trial comparing the effects of energy restriction and resveratrol. *Nutrients.* 2023;15(13):1-16.
51. Mengozzi A, Costantino S, Paneni F, Duranti E, Nannipieri M, Mancini R, et al. Targeting SIRT1 rescues age and obesity induced microvascular dysfunction in ex vivo human vessels. *Circ Res.* 2022;131(6):476–91.
52. Lee IH. Mechanisms and disease implications of sirtuin-mediated autophagic regulation. *Exp Mol Med.* 2019;5:1-11.
53. García BI, Ruiz M, Pedraza CJ, Santiago OE, Mendoza VM. Effect of resveratrol on markers of oxidative stress and sirtuin 1 in elderly adults with type 2 diabetes. *Int J Mol Sci.* 2023;24(8):1-15.
54. Bülow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. *J Histochem Cytochem.* 2019;67: 643–61.
55. Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in Chronic Kidney Disease: pathophysiology and therapeutic targets. *J Clin Med.* 2024;13:1-29.
56. Li P, Liu Y, Qin X, Chen K, Wang R, Yuan L, et al. SIRT1 attenuates renal fibrosis by repressing HIF-2 α . *Cell Death Discov.* 2021;7(1):1-10.
57. Haraguchi R, Kohara Y, Matsubayashi K, Kitazawa R, Kitazawa S. New insights into the pathogenesis of diabetic nephropathy: Proximal renal tubules are primary target of oxidative stress in diabetic kidney. *Acta Histochem Cytochem.* 2020;53(2):21–31.
58. Yang Y, Huang J, Xie L, Wang Y, Guo S, Wang M, et al. Nicotinamide protects against diabetic kidney disease through regulation of Sirt1. *Endocrine.* 2024;85:638-48.
59. Fu B, Yang J, Chen J, Lin L, Chen K, Zhang W, et al. Preventive effect of Shengkang injection against high glucose-induced senescence of renal tubular cells. *Front Med.* 2019;13(2):267–76.

60. Hasegawa K, Tamaki M, Shibata E, Inagaki T, Minato M, Yamaguchi S, et al. Ability of NAD and Sirt1 to epigenetically suppress albuminuria. *Clin Exp Nephrol*. 2024;28:599–607.
61. Hasegawa K. Novel tubular–glomerular interplay in diabetic kidney disease mediated by sirtuin 1, nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017. *Clin Exp Nephrol*. 2019;23:987–94.
62. Lopes-Gonçalves G, Costa-Pessoa JM, Pimenta R, Tostes AF, Silva EM, Ledesma FL, et al. Evaluation of glomerular sirtuin-1 and claudin-1 in the pathophysiology of nondiabetic focal segmental glomerulosclerosis. *Sci Rep*. 2023;13(1):1-14.
63. Ren H, Shao Y, Wu C, Lv C, Zhou Y, Wang Q. VASH-1 regulates oxidative stress and fibrosis in diabetic kidney disease via SIRT1/HIF1 α and TGF β 1/Smad3 signaling pathways. *Front Mol Biosci*. 2020;7:1-16.
64. Park CH, Yoo TH. TGF-B inhibitors for therapeutic management of kidney fibrosis. *Pharmaceuticals*. 2022;15:1-17.
65. Tang J, Liu F, Cooper ME, Chai Z. Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF- β) and related molecules. *Expert Opin Ther Targets*. 2022;26:721–38.
66. Zhao L, Zou Y, Liu F. Transforming Growth Factor-Beta1 in diabetic kidney disease. *Front Cell Dev Biol*. 2020;8:1-10.
67. Zhang Y, Dai Y, Raman A, Daniel E, Metcalf J, Reif G, et al. Overexpression of TGF-b1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease. *Am J Physiol Renal Physiol*. 2020;319:135-46.
68. Zhang YY, Yu Y, Yu C. Antifibrotic roles of RAAS blockers: update. *Adv Exp Med Biol*. 2019;1165:671–91.
69. Mukoyama M, Kuwabara T. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?. *Hypertension Res*. 2022;45:1072–5.
70. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF- β : The master regulator of fibrosis. *Nat Rev Nephrol*. 2016;12:325–38.

71. Zullo A, Mancini FP, Schleip R, Wearing S, Klingler W. Fibrosis: Sirtuins at the checkpoints of myofibroblast differentiation and profibrotic activity. *Wound Repair Regen.* 2021;29(4):650–66.
72. Wang J, Wang S, Wang J, Xiao M, Guo Y, Tang Y, et al. Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus. *Front Endocrinol.* 2021;11:1-13
73. Ren H, Shao Y, Ma X, Yang M, Liu Y, Wang Q. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios. *J Diabetes Complications.* 2019;33(7):477–84.
74. Zhang J, Zhang L, Zha D, Wu X. Inhibition of miRNA-135a-5p ameliorates TGF- β 1-induced human renal fibrosis by targeting SIRT1 in diabetic nephropathy. *Int J Mol Med.* 2020;46(3):1063–73.
75. Ren Y, Du C, Shi Y, Wei J, Wu H, Cui H. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress. *Int J Mol Med.* 2017;39(5):1317–24.
76. Fan J, Wei S, Zhang X, Chen L, Zhang X, Jiang Y, et al. Resveratrol inhibits TGF- β 1-induced fibrotic effects in human pterygium fibroblasts. *Environ Health Prev Med.* 2023;28:1-9.
77. Ashrafizadeh M, Najafi M, Orouei S, Zabolian A, Saleki H, Azami N, et al. Resveratrol modulates transforming growth factor-beta (TGF- β) signaling pathway for disease therapy: A new insight into its pharmacological activities. *Biomedicines.* 2020;8:1-25.
78. Bielach-Bazyluk A, Zbroch E, Czajkowska K, Koc-Zorawska E, Kakareko K, Rosolowska AR, et al. Serum sirtuin 1 is independently associated with intact pth among patients with chronic kidney disease. *Clin Interv Aging.* 2021;16:525–36.
79. Shanmugasundaram K, Talwar A, Madan K, Bade G. Pulmonary function and inflammatory biomarkers in post pulmonary tuberculosis sequelae. *Tuberc Respir Dis.* 2022;85:175-184.
80. Dubey K, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada P. Correction on metabolic acidosis improves muscle mass and renal function

in chronic kidney disease stages 3 and 4 ; a randomized controlled trial. *Nephrol Dial Transplant*. 2020;35:121-9.

81. Zhang Y, Yu C, Li X. Kidney aging and chronic kidney disease. *Int J Mol Sci*. 2024;25:1-28.
82. Lewandowsky M, Krenn S, Kurnikowski A, Bretschneider P, Sattler M, Schwaiger E, et al. Chronic kidney disease is more prevalent among women but more men than women are under nephrological care: Analysis from six outpatient clinics in Austria 2019. *Cent Eur J Med*. 2022;89-96
83. Hockham C, Bao L, Tikun A, Badve S, Bello A, Jardine M, et al. Sex differences in chronic kidney disease prevalence in Asia : a systematic review and meta analysis. *Clin Kidney J*. 2022;15(6):1144-51.
84. Merz N, Dember L, Ingelfinger J, Vinson A, Neugarten J, Sandberg K, et al. Sex and the kidneys:current understanding and research opportunities. *Nat Rev Nephrol*. 2019;1-8
85. Priyono D, Yerizel E, Harun H, Suharti N. Effect of Ramadhan fasting on malondialdehyde, poly(ADPribose) polymerase, sirtuin-1, nuclear receptor subfamily 1 group D member 1 and transforming growth factor beta in chronic kidney disease : a prospective cohort study. *Acta Med Indones-Indones J Intern Med*. 2025;57(2):228-36.
86. Kurella M, Lo J, Chertow G. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. *J Am Soc Nephrol*. 2005;16:2134-40.
87. Okawa Y, Mitsuhashi T. Association between blood pressure and new onset of chronic kidney disease in non-diabetic Japanese adults: a population based longitudinal study from 1998 to 2023. *Nutr Metab Cardiovasc Dis*. 2024;34:2395-2404.
88. Fathy SA, Ibrahim DM, Elkhayat WA, Ahmed HS. Association between serum sirt 1 and advanced glycation end products levels in type 2 diabetic nephropathy patients. *Int J Biosci*. 2017;10:398–404.
89. Bazyluk A, Czajkowska K, Zorawska E, Hryszko T, Zbroch E. Elevated Sirtuin 1 levels in patients with chronic kidney disease, including on peritoneal

dialysis: association with cardiovascular risk and peritoneal fibrosis.
Int J Mol Sci. 2025;1-17

90. Morevati M, Fang E, Mace M, Kanbay M, Gravesen E, Nordholm A, et al. Roles of NAD⁺ in acute and chronic kidney disease. Int J Mol Sci. 2023; 1- 26.
91. He W, Wang Y, Zhang M, You L, Davis L, Fan H, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010; 1056-68.
92. Chuang P, Xu J, Dai Y, Jia F, Mallipatu S, Yacoub R, et al. In vivo RNA interference models of inducible and reversible sirt1 knockdown in kidney cells. Am J Pathol. 2014;1940-56
93. Ko Y, Mohtat D, Suzuki M, Park A, Izquierdo M, Han S, et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol. 2013;1-14
94. Yamakuchi M, Lowenstein C. MiR-34, SIRT1 and p53. Cell cycle. 2009; 712- 5.
95. Takahashi R, Kanda T, Komatsu M, Itoh T, Minakuchi H, Urai H, et al. The significance of NAD⁺ metabolites and nicotinamide N-methyltransferase in chronic kidney disease. Sci Rep. 2022;1-19
96. Elibol B, Kilic U. High level of SIRT1 expression as a protective mechanism against disease-related conditions. Front. Endocrinol. 2018;9:1-7
97. Elkholy O, Attia G, Ibrahim W, Selim A. Association of sirt 1 gene polymorphism with the pathogenesis of diabetic nephropathy. Int J Sci Res. 2022;10: